Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


  • Sort by Product ID
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • United States, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected musculoskeletal diseases/disorders.

    January 1, 2013
    Find out more
  • European Markets for Prosthetic Vascular Grafts

    $3,850.00

    Prosthetic vascular grafts, made of synthetic or biological materials, are used to bypass or replace segments of blood vessels in kidney failure patients requiring hemodialysis access as well as those undergoing treatment for aneurysms or vascular occlusions.

    July 1, 2013
    Find out more
  • U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

    $3,750.00

    The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.

    July 1, 2013
    Find out more
  • United States, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected neurological diseases/disorders.

    January 1, 2013
    Find out more
  • U.S. Surgical Procedure Volumes

    $4,750.00

    This report presents the most common surgical procedures performed in the United States (U.S.) as well as an overview of the etiology and epidemiology of selected diseases/disorders, prevailing surgical approaches/techniques, and evolving procedural utilization trends.

    November 1, 2015
    Find out more
  • U.S. Markets for Diagnostic Oncology-Related X-Ray-Based Imaging Products

    $3,750.00

    Discoveries in molecular medicine in recent years have allowed researchers to study the genetic/chromosomal alterations that trigger the transformation of normal cells into malignant cells, which ultimately has led to the understanding that cancer—of which there are more than 100 forms—is a disease of the cellular genome.

    March 1, 2013
    Find out more
  • France, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in France

    November 1, 2012
    Find out more
  • Germany, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries

    November 1, 2012
    Find out more
  • U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators

    $3,750.00

    The scope of this report includes tissue-engineered skin replacements and substitutes (i.e., epidermal equivalents, dermal equivalents, and multilayer equivalents) and active wound repair modulators.

    February 1, 2013
    Find out more
  • Germany, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries

    December 3, 2012
    Find out more
  • Italy, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries

    November 1, 2012
    Find out more
  • Italy, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Italy; incidence and prevalence figures are compared with those of the Benelux countries

    December 3, 2012
    Find out more
  • Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries

    November 1, 2012
    Find out more
  • Spain, Neurological Market Opportunities: Disease Incidence and Prevalence, And Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Spain

    December 3, 2012
    Find out more
  • US Neurointerventional Devices Market, September 2016

    $4,750.00

    Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain.

    September 21, 2016
    Find out more
  • United Kingdom, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries

    December 3, 2012
    Find out more
  • Datamonitor Oncology Pathways in the US - Friend or Foe for Pharma

    Oncology Pathways in the US – Friend or Foe for Pharma

    $7,500.00

    This strategy report focuses on Oncology Pathways in the US including management of oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology pathways. 

    July 31, 2015
    Find out more
  • Key Trends in European Market Access

    $2,995.00

    This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.

    January 26, 2016
    Find out more
  • kol-bmt-licensing-trends

    Datamonitor Big Pharma Licensing Trends

    $3,000.00

    This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.

    February 23, 2016
    Find out more
  • Datamonitor Accountable Care Organizations - What Impact on Pharma

    Accountable Care Organizations – What Impact on Pharma

    $7,500.00

    This strategy report focuses Accountable Care Organizations and what impact they will have on pharma including an evaluation of ACOs’ structures, sizes, cultures, and risks.

    July 16, 2015
    Find out more
  • Immuno-Oncology Overview

    $7,500.00

    Immuno-oncology is an area of medicine that focuses on the development of therapies that improve the body’s ability to generate an immune response against cancer (Eggermont and Finn, 2012).

    December 13, 2017
    Find out more
  • Datamonitor Biosimilars Market Access in the US

    Biosimilars Market Access in the US

    $2,995.00

    This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.

    October 23, 2015
    Find out more
  • Datamonitor Malignant Melanoma Pricing and Reimbursement

    Malignant Melanoma Pricing, Reimbursement and Access

    $2,995.00

    This strategy report focuses on Malignant Melanoma Pricing and Reimbursement including how immunotherapies are changing melanoma treatment paradigms with market conext in the US, Japan, and five major EU markets.

    September 30, 2015
    Find out more
  • Current and Emerging U.S. Markets for Myocardial Revascularization, Repair, and Regeneration Products and Therapies

    $4,750.00

    Approximately 16.3 million adults in the United States (U.S.) suffer from coronaryheart disease (CHD), a type of cardiovascular disease that is associated with areduction in blood flow through the vasculature of the heart (ischemic heart disease).

    March 1, 2013
    Find out more
  • Celgene

    $3,000.00

    PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.

    October 8, 2018
    Find out more
  • Allergan

    $3,000.00

    PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.

    October 10, 2018
    Find out more
  • Company Analysis: Gilead

    $3,000.00

    PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
  • Mid Pharma Outlook

    $3,000.00

    Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.

    September 28, 2016
    Find out more
  • Company Analysis: UCB

    $3,000.00

    PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

    January 25, 2021
    Find out more
  • Q2 2016 Earnings Previews

    $3,000.00

    Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.

    September 28, 2016
    Find out more
  • Orphan Drug Market Outlook to 2017

    $3,000.00

    Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition. 

    September 28, 2016
    Find out more
  • Big Pharma Outlook 2015

    $3,000.00

    Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets.

    September 28, 2016
    Find out more
  • Company Analysis : AbbVie

    $3,000.00

    PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.

    July 15, 2020
    Find out more
  • Beraprost 314d

    Read More

    Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…

    June 19, 2015
    Find out more
  • Company Analysis: AstraZeneca

    $3,000.00

    PharmaVitae explores AstraZeneca’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
  • Company Analysis: Bayer

    $3,000.00

    PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.

    January 25, 2021
    Find out more
  • Dalvance

    Read More

    Dalvance is a second-generation, semi-synthetic lipoglycopeptide antibacterial compound of the same class as vancomycin. The drug inhibits the formation of, and disrupts the integrity of…

    September 10, 2014
    Find out more
  • Company Analysis: Bristol-Myers Squibb

    $3,000.00

    PharmaVitae explores Bristol-Myers Squibb’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
  • Company Analysis: Eli Lilly

    $3,000.00

    PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
  • D/C/F/TAF

    Read More

    D/C/F/TAF is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), the two nucleoside reverse transcriptase inhibitors…

    December 11, 2015
    Find out more
  • DCVAC/PCa

    Read More

    DCVAC/PCa is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells…

    January 18, 2018
    Find out more
  • Company Analysis: Merck & Co

    $3,000.00

    PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
  • Delafloxacin

    Read More

    Delafloxacin is a novel broad-spectrum fluoroquinolone that prevents bacterial DNA synthesis through its equal inhibitory effect against the enzymes topoisomerase II (DNA gyrase) and IV.

    September 10, 2014
    Find out more
  • Delzicol/Asacol HD

    Read More

    This product profile relates to the mesalamine franchise that covers Delzicol (mesalamine; Actavis), Asacol (mesalamine; Zeria/Kyowa Hakko Kirin), and Asacol HD (mesalamine; Actavis/Zeria)…

    May 1, 2015
    Find out more
  • Company Analysis: Novo Nordisk

    $3,000.00

    PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    January 25, 2021
    Find out more
Page 2 of 29
Page 2 of 29‹1234›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top